drugset / Trial / NCT03459222
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Timeline
- Start
- 2018-05-30
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | LINRODOSTAT | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |
Indications
No indication recorded.